
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 17
Selected: 0
NCT ID | Title | ||
---|---|---|---|
NCT02638220 | Cerebrotendinous Xanthomatosis (CTX) Prevalence Study | ||
NCT05856760 | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | ||
NCT05562362 | Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension | ||
NCT04663204 | A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy | ||
NCT06548022 | Rare Group Problem Management Plus | ||
NCT05003986 | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | ||
NCT03041116 | Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants | ||
NCT05630612 | ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) | ||
NCT02998710 | Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA) | ||
NCT05368038 | ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | ||
NCT01613118 | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | ||
NCT03762850 | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | ||
NCT03493685 | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | ||
NCT06247085 | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment | ||
NCT06431893 | A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥12 to ≤65 Years of Age with Classical Homocystinuria (HCU) | ||
NCT05200871 | Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) | ||
NCT03406611 | Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE) |